SCHEMBL3397464

SCHEMBL3397464

Ic1ccccc1-c1nn[nH]n1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.73
MEN1 O00255 2/20 0.73
KMT2A Q03164 2/20 0.73
L3MBTL1 Q9Y468 1/20 0.73
PBRM1 Q86U86 1/20 0.61
IDO1 P14902 1/20 0.61
GAA P10253 1/20 0.61
LDHA P00338 1/20 0.61
HPGDS O60760 1/20 0.49
KDM4E B2RXH2 2/20 0.47
ADH5 P11766 1/20 0.47
XDH P47989 2/20 0.46
PKM P14618 1/20 0.46
GP6 Q9HCN6 1/20 0.46
POLB P06746 1/20 0.44
GPR35 Q9HC97 2/20 0.44
TAS2R14 Q9NYV8 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2645793 0.76 MEN1 (0.73) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL2645790 0.76 ALDH1A1 (0.73) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL30153550 0.76 MEN1 (0.80) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL8429622 0.76 GAA (1.00) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL8294492 0.76 ALDH1A1 (0.73) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL14262602 0.76 MEN1 (0.73) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL14844440 0.76 ALDH1A1 (0.73) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL4206359 0.76 PBRM1 (1.00) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL8294486 0.76 LDHA (1.00) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL6472013 0.76 IDO1 (1.00) ALDH1A1MEN1KMT2AL3MBTL1PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2246348-A1 Coupling reactions useful in the preparation of (1h-tetrazol-5-yl)-biphenyl derivatives Novartis AG (CH) 2010-11-03 EP disclosed
US-20100152458-A1 COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL) BIPHENYL DERIVATIVES NOVARTIS PHARMACEUTICALS CORPORATION 2010-06-17 US disclosed
US-7700784-B2 Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives NOVARTIS AG (CH) 2010-04-20 US disclosed
CN-100528868-C Coupling reactions useful in the preparation of (1h-tetrazol-5-yl)-biphenyl derivatives NOVARTIS AG (CH) 2009-08-19 CN disclosed
US-20070129413-A1 Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives NOVARTIS PHARMACEUTICALS CORPORATION 2007-06-07 US disclosed
CN-1914197-A Coupling reactions useful in the preparation of (1h-tetrazol-5-yl)-biphenyl derivatives NOVARTIS AG (CH) 2007-02-14 CN disclosed
EP-1716140-A1 COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL)-BIPHENYL DERIVATIVES Novartis AG (CH) 2006-11-02 EP disclosed
WO-2005075462-A1 COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL)-BIPHENYL DERIVATIVES NOVARTIS AG (CH) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152458-A1 COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL) BIPHENYL DERIVATIVES AGTR1, AGTR2, AGT ALDH1A1 633/4885MEN1 2390/4885KMT2A 2815/4885
US-20070129413-A1 Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives AGTR1, AGTR2, AGT ALDH1A1 1285/4885MEN1 2139/4885KMT2A 3213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.